Breitfeld Philip P.
Known title: DirectorCIK: 0001690133
Associated companies
Transaction History
| CSBR | ▼ Sell | Other | 4,150 | $0 | 3/25/2025 | View on chart |
| CSBR | ▲ Buy | Option Exercise | 8,333 | $27K | 10/12/2022 | View on chart |
| CSBR | ▼ Sell | Tax Withholding | 3,562 | $27K | 10/12/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
Champions Oncology Highlighted in Global PDX Models Shift
Champions Oncology was highlighted in a Yahoo article that discusses the shift toward patient‑derived xenograft (PDX) models in precision oncology. The story compares the company with peers like Charles River, Crown Bioscience, The Jackson Laboratory and Oncodesign, indicating growing industry focus on PDX‑based research. This comparison suggests Champions may benefit from increased demand for its precision oncology solutions. No new financial data were disclosed.
Champions Oncology Highlighted in Global PDX Models Shift. Champions Oncology was highlighted in a Yahoo article that discusses the shift toward patient‑derived xenograft (PDX) models in precision oncology. The story compares the company with peers like Charles River, Crown Bioscience, The Jackson Laboratory and Oncodesign, indicating growing industry focus on PDX‑based research. This comparison suggests Champions may benefit from increased demand for its precision oncology solutions. No new financial data were disclosed.